We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cheek Swab Test Could Detect Risk of Preterm Birth

By LabMedica International staff writers
Posted on 09 Dec 2024
Print article
Image: A potential epigenetic biomarker has been found for preeclampsia in pregnancy (Photo courtesy of 123RF)
Image: A potential epigenetic biomarker has been found for preeclampsia in pregnancy (Photo courtesy of 123RF)

Preeclampsia is a serious condition that can be life-threatening and often results in preterm births, which are defined as births occurring before 37 weeks of gestation. Babies born prematurely frequently face long-term health challenges, including intellectual and developmental disabilities. While preeclampsia is responsible for approximately 8%-10% of preterm births, these are typically among the earliest-term births and tend to have more severe health complications. Currently, preeclampsia is diagnosed based on symptoms like elevated blood pressure, which usually manifests during the second trimester. Unfortunately, the condition can sometimes go unnoticed until it escalates into a medical emergency. However, a new study analyzing cheek swabs from pregnant women has identified a potential epigenetic biomarker for preeclampsia. With this biomarker, clinicians could implement management strategies during the first and early second trimester, potentially delaying preterm birth.

While clinical trials are necessary to validate these findings, the research conducted by scientists at Washington State University (Pullman, WA, USA) offers promising possibilities for an early diagnostic test for preeclampsia. The study, published in Environmental Epigenetics, involved the collection of cheek cells via swabs from 49 new mothers after delivery. Among this group, 13 women had preeclampsia and delivered prematurely, while the remaining mothers had preterm births but no preeclampsia. A control group of 13 women had full-term deliveries. The research team analyzed the epigenetic changes in these cells, focusing on molecular factors that influence gene activity but are independent of DNA sequence.

The study revealed that mothers with preeclampsia exhibited 389 distinct epigenetic changes in specific DNA methylation regions. These modifications were not present in the mothers without the condition. Furthermore, the set of modifications showed only a 15% overlap with the epigenetics of mothers who experienced preterm birth but did not have preeclampsia, suggesting that these changes are directly associated with preeclampsia. Previously, the team had identified a potential biomarker for the risk of preterm birth. The researchers now aim to conduct a clinical trial to confirm the findings from both this and the earlier study. Ultimately, they hope to develop a cheek swab test to detect these risks earlier, enabling preventative treatments that could improve maternal and infant health outcomes.

“If we have a biomarker for the susceptibility of preeclampsia, then there are some clinical management practices in the first trimester and early second trimester that could delay a preterm birth,” said corresponding author Michael Skinner, a Washington State University biologist. “Preterm birth, which is now more than 10% of all pregnancies, is causing to a large degree, the later-life health issues of every one of those preterm individuals. This is not only an issue for the individuals involved, but potentially a general health issue, and these types of steps forward could really have a big impact in reducing the disease burden on our population.”

Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Gold Member
ZIKA Virus Test
ZIKA ELISA IgG
New
Gold Member
Measles Test
MEASLES ELISA IgG/IgM
New
Borrelia Burgdorferi Test
AESKULISA Borrelia-M

Print article

Channels

Microbiology

view channel
Image: The breakthrough system offers a faster way to diagnose bloodborne infections (Photo courtesy of Melio)

Culture-Free Platform Rapidly Identifies Blood Stream Infections

Neonatal sepsis is a life-threatening condition that results from bloodstream infections in newborns under 28 days old. Due to their immature immune systems, newborns are especially vulnerable to infections.... Read more

Pathology

view channel
Image: The AI tool can search through data and histology images for much more precise information on cancer treatment effectiveness (Photo courtesy of Shutterstock)

AI Tool Analyzes 30K Data Points Per Medical Imaging Pixel in Cancer Search

A new artificial intelligence (AI)-powered tool can detect cell-level characteristics of cancer by analyzing data from very small tissue samples, some as tiny as 400 square micrometers, equivalent to the... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more

Industry

view channel
Image: The game-changing immunoassay diagnostics platform delivers results from whole blood sample in 10 minutes (Photo courtesy of SpinChip)

bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics

bioMérieux (Marcy l’Étoile, France) has agreed to acquire SpinChip Diagnostics (Oslo, Norway), the developer of a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.